Last edition
News about "Adverse Events (AEs)"
Japan Approves Rituxan for Steroid-Dependent Nephrotic Syndrome in Adults
Rituxan (rituximab) IV 100 mg and 500 mg receives regulatory approval for adult-onset frequently relapsing or steroid-dependent nephrotic syndrome, with phase 3 data showing an 87.4 percent relapse-free rate at week 49.
Adverse Events (AEs) | 20/06/2026 | By News Bureau | 105
China Approves Nucala from GSK for Adult COPD Treatment
China has approved Nucala (mepolizumab) for adult COPD, supported by phase-III MATINEE and METREX trials showing reduced exacerbations in patients with blood eosinophil counts from 150 cells/µL.
Adverse Events (AEs) | 06/01/2026 | By News Bureau | 342
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy